Pasar al contenido principal

AVANCES EN EL CONOCIMIENTO INMUNOLOGICO Y MOLECULAR PARA EL CONTROL DE LA ENFERMEDAD DE CHAGAS.

PID2019-109090RB-I00

•
Nombre agencia financiadora Agencia Estatal de Investigación
Acrónimo agencia financiadora AEI
Programa Programa Estatal de I+D+i Orientado a los Retos de la Sociedad
Convocatoria Proyectos de I+D+i (Generación de Conocimiento y Retos Investigación)
Año convocatoria 2019
Plan Estatal 2017-2020 Plan Estatal de Investigación Científica y Técnica y de Innovación
Centro beneficiario AGENCIA ESTATAL CONSEJO SUPERIOR DE INVESTIGACIONES CIENTIFICAS (CSIC)

Resultados relacionados

Resultados totales (Incluyendo duplicados): 4
Encontrada(s) 1 página(s)

DIGITAL.CSIC. Repositorio Institucional del CSIC
Publicación Artículo científico (JournalArticle)

The expression of immune response genes in patients with chronic Chagas disease is shifted toward the levels observed in healthy subjects as a result of treatment with Benznidazole

  • Gómez, Inmaculada
  • Egui, Adriana
  • Palacios, Génesis
  • Carrilero, Bartolomé
  • Segovia, Manuel
  • Carmelo, Emma
  • López López, Manuel Carlos
  • Thomas, María del Carmen
[Introduction] Chagas disease, caused by the Trypanosoma cruzi parasite infection, is a potentially life-threatening neglected tropical disease with a worldwide distribution. During the chronic phase of the disease, there exists a fragile balance between the host immune response and parasite replication that keeps patients in a clinically-silent asymptomatic stage for years or even decades. However, in 40% of patients, the disease progresses to clinical manifestations mainly affecting and compromising the cardiac system. Treatment is recommended in the chronic phase, although there are no early markers of its effectiveness. The aim of this study is to identify differential expression changes in genes involved in the immune response in antigen-restimulated PBMC from chronic patients with Chagas disease due to benznidazole treatment., [Methods] Thus, high-throughput real-time qPCR analysis has been performed to simultaneously determine global changes in the expression of 106 genes involved in the immune response in asymptomatic (IND) and early cardiac manifestations (CCC I) Chagas disease patients pre- and post-treatment with benznidazole., [Results and discussion] The results revealed that 7 out of the 106 analyzed genes were differentially expressed (4 up- and 3 downregulated) after treatment in IND patients and 15 out of 106 (3 up- and 12 downregulated) after treatment of early cardiac Chagas disease patients. Particularly in CCC I patients, regulation of the expression level of some of these genes towards a level similar to that of healthy subjects suggests a beneficial effect of treatment and supports recommendation of benznidazole administration to early cardiac Chagas disease patients. The data obtained also demonstrated that both in asymptomatic patients and in early cardiac chronic patients, after treatment with benznidazole there is a negative regulation of the proinflammatory and cytotoxic responses triggered as a consequence of T. cruzi infection and the persistence of the parasite. This downregulation of the immune response likely prevents marked tissue damage and healing in early cardiac patients, suggesting its positive effect in controlling the pathology., The author(s) declare financial support was received for the research, authorship, and/or publication of this article. This work was supported by grant PID2019-109090RB-I00/AEI/10.13039/501100011033 from the Programa Estatal I+D+I, Spanish Ministry of Science, Innovation and Universities (MICINN) to (MT, ML, IG)., Peer reviewed
DIGITAL.CSIC. Repositorio Institucional del CSIC
Publicación Artículo científico (JournalArticle)

A guide for the generation of repositories of clinical samples for research on Chagas disease

  • Martínez-Peinado, Nieves
  • Gabaldón-Figueira, Juan Carlos
  • Thomas, María del Carmen
  • López López, Manuel Carlos
  • Alonso-Padilla, Julio
  • NHEPACHA Network
On behalf of the NHEPACHA Network (New Tools for the Diagnosis and Evaluation of Chagas Disease): et al., Chagas disease, caused by the parasite Trypanosoma cruzi, affects over 6 million people, mainly in Latin America. Two different clinical phases, acute and chronic, are recognised. Currently, 2 anti-parasitic drugs are available to treat the disease (nifurtimox and benznidazole), but diagnostic methods require of a relatively complex infrastructure and trained personnel, limiting its widespread use in endemic areas, and the access of patients to treatment. New diagnostic methods, such as rapid tests (RDTs) to diagnose chronic Chagas disease, or loop-mediated isothermal amplification (LAMP), to detect acute infections, represent valuable alternatives, but the parasite's remarkable genetic diversity might make its implementation difficult. Furthermore, determining the efficacy of Chagas disease treatment is complicated, given the slow reversion of serological anti-T. cruzi antibody reactivity, which may even take decades to occur. New biomarkers to evaluate early therapeutic efficacy, as well as diagnostic tests able to detect the wide variety of circulating genotypes, are therefore, urgently required. To carry out studies that address these needs, high-quality and traceable samples from T. cruzi-infected individuals with different geographical backgrounds, along with associated clinical and epidemiological data, are necessary. This work describes the framework for the creation of such repositories, following standardised and uniform protocols, and considering the ethical, technical, and logistic aspects of the process. The manual can be adapted according to the resources of each laboratory, to guarantee that samples are obtained in a reproducible way, favouring the exchange of data among different work groups, and their generalizable evaluation and analysis. The main objective of this is to accelerate the development of new diagnostic methods and the identification of biomarkers for Chagas disease., MCT and MCL were supported by Grant PID2019-109090RB-100/AEI/10.13039/ 501100011033 from the Programa Estatal I+D+I, Spanish Ministry of Science and Innovation (MICINN). We acknowledge support from the grant CEX2018-000806-S funded by MCIN/AEI/ 10. 13039/501100011033. ILG, JCGF, NMP, JG, and JAP acknowledge support from the Generalitat de Catalunya through the CERCA Program. JCGF received support through a fellowship from “la Caixa” Foundation (ID 100010434, fellowship code: LCF/BQ/DI21/11860037)., With funding from the Spanish government through the "Severo Ochoa Centre of Excellence" accreditation (CEX2018-000806-S)., Peer reviewed
DIGITAL.CSIC. Repositorio Institucional del CSIC
Publicación Artículo científico (JournalArticle)

DNA G-quadruplexes in the genome of Trypanosoma cruzi as potential therapeutic targets for Chagas disease: Dithienylethene ligands as effective antiparasitic agents

  • Pérez Soto, Manuel
  • Ramos-Soriano, Javier
  • Peñalver, Pablo
  • Belmonte-Reche, Efres
  • O'Hagan, Michael P.
  • Cucchiarini, Anne
  • Mergny, Jean-Louis
  • Galán, M. Carmen
  • López López, Manuel Carlos
  • Thomas, María del Carmen
  • Morales, Juan Carlos
Chagas disease is caused by the parasite Trypanosoma cruzi and affects over 7 million people worldwide. The two actual treatments, Benznidazole (Bzn) and Nifurtimox, cause serious side effects due to their high toxicity leading to treatment abandonment by the patients. In this work, we propose DNA G-quadruplexes (G4) as potential therapeutic targets for this infectious disease. We have found 174 PQS per 100,000 nucleotides in the genome of T. cruzi and confirmed G4 formation of three frequent motifs. We synthesized a family of 14 quadruplex ligands based in the dithienylethene (DTE) scaffold and demonstrated their binding to these identified G4 sequences. Several DTE derivatives exhibited micromolar activity against epimastigotes of four different strains of T. cruzi, in the same concentration range as Bzn. Compounds L3 and L4 presented remarkable activity against trypomastigotes, the active form in blood, of T. cruzi SOL strain (IC50 = 1.5-3.3 μM, SI = 25-40.9), being around 40 times more active than Bzn and displaying much better selectivity indexes., JCM thanks the funding by the Spanish Ministerio de Ciencia, Innovación y Universidades (PID2021-127109OB-I00). EBR received funding support from a Maria Zambrano fellowship, financed by NextGenerationEU/European Union. MCG thanks ERC-COG: 648239, EPSRC Funds EP/R043361/1, TS/R014329/1 and GCRF EP/T020288/1 for financial support and JRS thanks MSCA fellowship (project 843720-BioNanoProbes). A.C. and J.L.M. thank the generous benefactors of the Fondation X for their support. MCL and MCT were supported by grant PID2019-109090RB-I00/AEI/10.13039/501100011033 from the Programa Estatal I + D + I, Spanish Ministry of Science, Innovation and Universities (MICINN)., Peer reviewed
DIGITAL.CSIC. Repositorio Institucional del CSIC
Publicación Artículo científico (JournalArticle)

Evaluation of the accuracy of a multi-infection screening test based on a multiplex immunoassay targeting imported diseases common in migrant populations

  • Aguilar, Ruth
  • Cruz, Angeline
  • Jiménez, Alfons
  • Almuedo, Alex
  • Roca Saumell, Carme
  • Gigante López, Marina
  • Gasch, Oriol
  • Falcó, Gemma
  • Jiménez-Lozano, Ana
  • Martínez-Pérez, Angela
  • Sánchez-Collado, Consol
  • Tedesco, Andrea
  • López López, Manuel Carlos
  • Pinazo, María Jesús
  • Leonel, Thais
  • Bisoffi, Zeno
  • Färnert, Anna
  • Dobaño, Carlota
  • Requena-Méndez, Ana
[Background]We aimed to evaluate the performance of a novel multiplex serological assay, able to simultaneously detect IgG of six infections, as a screening tool for imported diseases in migrants., [Methods] Six panels of 40 (n = 240) anonymized serum samples with confirmed infections were used as positive controls to assess the multiplex assay's sensitivity. One panel of 40 sera from non-infected subjects was used to estimate the seropositivity cutoffs, and 32 non-infected sera were used as negative controls to estimate each serology's sensitivity and specificity. The multi-infection screening test was validated in a prospective cohort of 48 migrants from endemic areas.The sensitivity of the Luminex assay was calculated as the proportion of positive results over all positive samples identified by reference tests. The specificity was calculated using 32 negative samples. Uncertainty was quantified with 95 % confidence intervals using receiver operating characteristic analyses., [Results] The sensitivity/specificity were 100 %/100 % for HIV (gp41 antigen), 97.5 %/100 % for Hepatitis B virus (HBV-core antigen), 100 %/100 % for Hepatitis C virus (HCV-core antigen), 92.5 %/90.6 % for strongyloidiasis [31-kDa recombinant antigen (NIE)], 97.5 %/100 % for schistosomiasis (combined serpin Schistosoma mansoni and S.haematobium antigens) and 95 %/90.6 % for Chagas disease [combined Trypanosoma cruzi kinetoplastid membrane protein-11 (KMP11) and paraflagellar rod proteins 2 (PFR2) antigens]. In the migrant cohort, antibody response to the combination of the T.cruzi antigens correctly identified 100 % individuals, whereas HBV-core antigen correctly identified 91.7 % and Strongyloides-NIE antigen 86.4 %., [Conclusions] We developed a new, robust and accurate 8-plex Luminex assay that could facilitate the implementation of screening programmes targeting migrant populations., This study was supported by two grants from Instituto de Salud Carlos III (ISCIII), co-financed by the European Regional Development Fund (FEDER) from the European Union, through the “Fondo de Investigación para la Salud (FIS)”, PI17/02020 and PI20/00866. This research team was supported by CIBER-Consorcio Centro de Investigación Biomédica en Red-(CB 2021), Instituto de Salud Carlos III, Ministerio de Ciencia e Innovación and Unión Europea. ISGlobal receives support from the Spanish Ministry of Science and Innovation through the “Centro de Excelencia Severo Ochoa 2019–2023” Program (CEX2018-000806-S), and support from the Generalitat de Catalunya through the CERCA Program. Authors from IRCCS Sacro Cuore Don Calabria Hospital were supported by the Italian Ministry of Health “Fondi Ricerca corrente-L2P4”. ARM receives funding from the Strategic Research Program in Epidemiology at Karolinska Institutet. MCL was supported by the Programa Estatal I + D + I, Spanish Ministry of Science and Innovation and FEDER (PID2019-109090RB-I00/AEI/10.13039/501100011033)., With funding from the Spanish government through the "Severo Ochoa Centre of Excelence" accreditation (CEX2018-000806-S), Peer reviewed